🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Este viernes en #TIROxMDs discutiremos las próximas guías de la Asociación Americana de Tiroides (ATA). Una sesión clave para: endocrinólogos, cirujanos, especialistas en medicina nuclear, patólogos y oncólogos. ¿Qué cambia? ¿Qué permanece? ¿Cómo impactará nuestra práctica

New SEER study from JAMA Network Open re-demonstrates an increase in the incidence of colorectal cancer among young adults in the US over the last 25 years. This database captures about 50% of the US population, so it's an accurate tool for this task. Two big ongoing questions:

The ultimate ADC review! 40 years of ADC. Must read for residents. 10.1158/2159-8290.CD-24-0708 Dr Akhil Santhosh Dr Vineet Govinda Gupta Valame MD DNB Dr Amol Akhade Ashish Singh Josh Thomas Georgy Ajoy Oommen John

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: a pooled analysis of TRIBE and TRIBE2 studies - European Journal of Cancer ejcancer.com/article/S0959-…

1/ How ADCs Actually Work - it’s more than just payload internalization. 💣The brutal elegance of a biological smart bomb A thread 🧵

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

Nonoperative Management of Mismatch Repair–Deficient Tumors in NEJM Ph 2 study, neoadjuvant dostarlimab (PD-1 inh) achieved 82% cCR and 80% organ preservation in stage I–III dMMR tumors, with 92% 2-year RFS; 44% had Lynch syndrome🧬 OncoAlert nejm.org/doi/full/10.10…

Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

Bookmark this. Excellent. 👇🏼👇🏼 Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers. ⁦Nature Reviews Cancer⁩ nature.com/articles/s4157…

#ASCO25 ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm Yelena Y. Janjigian MD ATOMIC #dMMR #CRCsm Frank Sinicrope, MD ➡️Clinical Science Symposium

Thrilled to share our latest Review on Gastric Cancer in the The Lancet covering the latest in the treatment and management of this illness Lizzy Smyth Kohei shitara Hanneke van Laarhoven Sheraz Markar Yelena Y. Janjigian MD & Izuma Nakayama. thelancet.com/journals/lance…

💢💢The result of a collaborative project among Sociedad SEEN Grupo GETNE aecirujanos SEOM SEMNIM #SEOR SEAP-IAP #AEU 📌Spanish consensus on the diagnosis and management of adrenocortical carcinoma 👉Free-access👉👉 erc.bioscientifica.com/view/journals/…

Honored and proud to be named a #FeaturedVoice for #ASCO25! Even more meaningful to share this journey with such an inspiring and diverse group of colleagues. Let’s amplify science, equity, and innovation together. Grateful for the opportunity—and the responsibility. See you in

El carcinoma adrenocortical es una neoplasia altamente compleja que requiere de la colaboración de diferentes especialidades. Ya publicado el consenso 🇪🇸 con participación de Grupo GETNE 👇🏻👇🏻👇🏻

Nueva fecha‼️ La sesión post-ENETS25 se celebrará el 19 de mayo. 🗓🔍👀 Os esperamos‼️

🗞️ Published in Cell Reports Medicine: SALSA, a new artificial intelligence tool developed by Radiomics Group for the automated and precise analysis of liver tumors. ➡️ linke.to/SALSAVHIO #RadiomicsVHIO

🔹 La Dra. Irene Carrasco durante su ponencia: "Manejo práctico de los sarcomas". 🔹 Comenzamos la mesa 4 del X Foro #OM3d. 🔹 Modera el Dr. Jaume Capdevilla (Jaume Capdevila) #Oncología #Sarcomas

🔹 El Dr. Jaume Capdevila (Jaume Capdevila ) nos comparte su perspectiva sobre "Manejo práctico del cáncer de tiroides". #OM3d #Oncología #CáncerDeTiroides

📅7.05.25 Resumir tumores neuroendocrinos en 10 minutos⚡en #OM3d y q modere Jaume Capdevila ➡️presidente Grupo GETNE ➡️coordinador de la mayoría de ensayos q comentas (TALENT, CABATEN, LEVEL...)😇 es más complicado que defender un examen de #Oncología en 10 minutos ante DeVita‼️